The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Musolino, A., Naldi, N., Bortesi, B., Pezzuolo, D., Capelletti, M., Missale, G., Laccabue, D., Zerbini, A., Camisa, R., Bisagni, G., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.8957 · Cited by 981
Research works printed but not linked: 17
- Romond, 2005, Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer, N Engl J Med, 353, 1673, 10.1056/NEJMoa052122 · DOI · Paper page
- Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 37, 687, 10.1016/S0140-6736(10)61121-X · DOI · Paper page
- Bianchini, 2014, The immune system and response to HER2-targeted treatment in breast cancer, Lancet Oncol, 15, e58, 10.1016/S1470-2045(13)70477-7 · DOI · Paper page
- Lehrnbecher, 1999, Variant genotypes of the low-affinity Fcgamma receptors in two control populations and a review of low-affinity Fc gamma receptor polymorphisms in control and disease populations, Blood, 94, 4220, 10.1182/blood.V94.12.4220.424k08_4220_4232 · doi:10.1182/blood.v94.12.4220.424k08_4220_4232
- Gianni, 2008, The “other” signaling of trastuzumab: antibodies are immunocompetent drugs, J Clin Oncol, 26, 1778, 10.1200/JCO.2007.15.7404 · DOI
- Nordstrom, 2011, Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties, Breast Cancer Res, 13, R123, 10.1186/bcr3069 · DOI · Paper page
- Tanner, 2004, Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer, Mol Cancer Ther, 3, 1585, 10.1158/1535-7163.1585.3.12 · DOI · Paper page
- Bruno, 2005, Population pharmacokinetics of trastuzumab in patient with HER2+ metastatic breast cancer, Cancer Chemother Pharmacol, 56, 361, 10.1007/s00280-005-1026-z · DOI · Paper page
- Agus, 2005, Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer, J Clin Oncol, 23, 2534, 10.1200/JCO.2005.03.184 · DOI · Paper page
- Leyland-Jones, 2003, Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel, J Clin Oncol, 21, 3965, 10.1200/JCO.2003.12.109 · DOI · Paper page
- Tabrizi, 2006, Elimination mechanisms of therapeutic monoclonal antibodies, Drug Discov Today, 11, 81, 10.1016/S1359-6446(05)03638-X · DOI · Paper page
- Keizer, 2010, Clinical pharmacokinetics of therapeutic monoclonal antibodies, Clin Pharmacokinet, 49, 493, 10.2165/11531280-000000000-00000 · DOI · Paper page
- Vugmeyster, 2012, Pharmacokinetics and toxicology of therapeutic proteins: Advances and challenges, World J Biol Chem, 3, 73, 10.4331/wjbc.v3.i4.73 · DOI · Paper page
- Baselga, 1996, Phase II study of weekly intravenous recombinant anti-p185HER monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer, J Clin Oncol, 14, 737, 10.1200/JCO.1996.14.3.737 · DOI · Paper page
- Pegram, 1998, Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment, J Clin Oncol, 16, 2659, 10.1200/JCO.1998.16.8.2659 · DOI · Paper page
- Carbonell Castellon, 2002, Efficacy and safety of 3-weekly herceptin (H) monotherapy in women with HER2-positive metastatic breast cancer (MBC): preliminary data from a phase II study, Proc Am Soc Clin Oncol, 21, 19a
- Ghahramani, 2003, Pharmacokinetics of Herceptin administered three-weekly compared to weekly: a simulation based on data from the clinical studies, Breast, 12, S40, 10.1016/S0960-9776(03)80128-5 · doi:10.1016/s0960-9776(03)80128-5
Cited by
Current treatment and recent progress in gastric cancer
Joshi, S. S., & Badgwell, B. D. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21657 · Cited by 1,677
HER2-targeted therapies — a role beyond breast cancer
Oh, D.-Y., & Bang, Y.-J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0268-3 · Cited by 1,081
Self-citationGastric cancer treatment: recent progress and future perspectives
Guan, W.-L., He, Y., & Xu, R.-H. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01451-3 · Cited by 944
HER2-Low Breast Cancer: Pathological and Clinical Landscape
Tarantino, P., Hamilton, E., Tolaney, S. M., Cortes, J., Morganti, S., Ferraro, E., Marra, A., Viale, G., Trapani, D., Cardoso, F., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.02488 · Cited by 791
Breast Cancer Treatments: Updates and New Challenges
Burguin, A., Diorio, C., & Durocher, F. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11080808 · Cited by 488
Metadata
- Authors
- Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., Stewart, S. J., Baughman, J. E., Lechleider, R. J., & Burris, H. A.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2017-04
- Volume
- 28
- Issue
- 4
- Pages
- 855-861
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2582248920
- Cited by
- 226
- References
- 3
- FWCI
- 9.48
- Type
- journal article
- Language
- en
- Open access
- bronze
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/open-access/userlicense/1.0/ (vor, 942 d)
- Funders
- MacroGenics, Inc.
- Green Cross Corp
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. https://app.cochat.ai/papers/10.1093/annonc/mdx002
- The paper
- Bang, Y. J., Giaccone, G., Im, S. A., Oh, D. Y., Bauer, T. M., Nordstrom, J. L., Li, H., Chichili, G. R., Moore, P. A., Hong, S., Stewart, S. J., Baughman, J. E., Lechleider, R. J., & Burris, H. A. (2017). First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors. Annals of Oncology. https://doi.org/10.1093/annonc/mdx002
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.